May 20, 2024 4:39pm

Ben Graham once said about the stock market, “over the short term, it's a voting machine, and over the long term, it's a weighing machine”

Never leave an investor uninformed! A trusted source of factual reporting!

The present and future value of RegMed Investors (RMi) NEWS sheds light on the stem, cell and gene therapy sector’s risks to share pricing and the sector’s upside acrobatics and downslides.

I write this blog/newsletter about – facts in evidence! 

 

 

I answer or qualify the sector’s equity’s movement; with an emphasis on which company is gaining or losing stride in your portfolio for the short and near-term

 

I also follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”

 

Monday: The Dow closed DOWN -195.90 points or -0.49%, the S&P closed UP +4.92 points or +0.09% while the Nasdaq closed UP +108.91 points or +0.65%

 

Henry’omics:

We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …

  • Monday's indexes closed mixed as many question whether the current outlook is sustainable.

 

Advance/Decline (A/D) Line:

  • Monday’s advance/decline line at the open was negative with 14 incliner, 17 decliners and 4 flats; ending with a negative close of 15 incliners, 16 decliners and 4 flats

 

Ebb and flow of MY covered sector cell and gene therapy session daily “endings”:

Q2/24: 8 positive and 6 negative closes

  • April; 16 negative and 6 positive closes

 

Key Metrics:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Monday, the IBB was up +0.60% and the XBI was up +1.22%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Monday was up +0.15 point or +1.25% at 12.14

 

Monday’s Closing Down (10 of 16):

  • CRISPR Therapeutics (CRSP -$0.75 after Friday’s +$0.55
  • Blueprint Medicine (BPMC -$0.70 after Friday’s -$1.68),
  • Sage Therapeutics (SAGE -$0.52 after Friday’s -$0.31
  • Ultragenyx Pharmaceuticals (RARE -$0.34 after Friday’s -$0.74
  • Intellia Therapeutics (NTLA -$0.33 after Friday’s +$0.05),
  • Caribou BioSciences (CRBU -$0.26),
  • uniQure NV (QURE -$0.16),
  • Agenus (AGEN -$0.16 after Friday’s +$0.36
  • Generation BIO (GBIO -$0.13),
  • BioLife Solutions (BLFS -$0.13),

Flat (4):

  • Harvard Apparatus RT (OTCQB: HRGN $0.00 after Friday's $0.00)
  • bluebird bio (BLUE)
  • Bellicum Pharmaceuticals (BLCM) – dropped)
  • Compass Therapeutics (CMPX $0.00 after Friday’s $0.00),

Monday’s Closing Up (10 of 15):

  • Vericel (VCEL +$2.78 after Friday’s +$0.74
  • Lenz Therapeutics (LENZ +$2.24),
  • Ionis Pharmaceuticals (IONS +$1.41 after Friday’s -$0.31),
  • Alnylam Pharmaceuticals (ALNY +$0.84 after Friday’s -$1.82),
  • Prime Medicine (PRME +$0.45 after Friday’s +$0.04),
  • Beam Therapeutics (BEAM +$0.22 after Friday’s +$0.83),
  • Adverum Biotechnologies (ADVM +$0.21 after Friday’s -$0.21
  • MiMedx (MDXG +$0.20),
  • Solid Biosciences (SLD +$0.17 after Friday’s -$0.35
  • AxoGen (AXGN +$0.16 after Friday’s +$0.07),

 

Q2/24 – May

  • (5/20) Monday closed negative with 15 incliners, 16 decliners and 4 flats

 

The BOTTOM LINE:  Anyone puzzled by the most recent sector moves has reason for feeling so; volatility sketches a sometimes-contradictory picture of the short-term.

  • I focus on “informing” news product, our users and our clients. We firmly believe that, if we build a great product … you will follow!

Today's session speaks for itself!

 

The top three (3) performing in the session:  

  • Monday: Vericel (VCEL), Lenz Therapeutics (LENZ) and Ionis Pharmaceuticals (IONS) 

The worst three (3) in the session:

  • Monday: CRISPR Therapeutics (CRSP), Blueprint Medicine (BLMC) and Sage Therapeutics (SAGE)

 

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.